Fig. 8.

GPR84 high risk inhibits anti-PD-1 efficiency. a–c RNA-seq data from patients with cancer that received anti-PD-1 or PD-L1 treatment were downloaded from the GEO database or European Genome-Phenome Archive, respectively. According to the GPR84 signature, cancer patients were divided into high- and low-risk groups, then overall survival was compared using Kaplan–Meier analysis. d Peripheral blood from patients receiving combination chemotherapy and anti-PD-1 was collected to examine the expression of GPR84 and PD-L1 in MDSCs. e Imaging data from patients with and without reaction after anti-PD-1 treatment (PD: progressive diseases; PR: partial response). Data are represented as mean ± SEM. *p < 0.05, ***p < 0.001